Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

Inclusion Criteria:

- Informed consent provided by the participant or the participant's legally acceptable
representative

- Age 55 years or older

- Possible/probable Alzheimer's Disease (AD)

- Community dwelling with a caregiver able and willing to accompany the participant on
all visits, if necessary. Caregiver must visit with the subject >5 times per week.

- Rosen Modified Hachinski score of 4 or less

- Imaging Study (CT or MRI) compatible with AD or age-related changes (absence of
significant abnormalities that may explain cognitive decline, such as multiple
lacunar infarcts or a single prior infarct >1 cubic cm, microhemorrhages or evidence
of a prior hemorrhage > 1 cubic cm, evidence of cerebral contusion encephalomalacia,
aneurysm, vascular malformation, or space occupying lesion such as an arachnoid cyst
or brain tumor).

- Adequate visual and auditory abilities to perform all aspects of the cognitive and
functional assessments

Exclusion Criteria:

- Significant neurological disease, other than AD, that may affect cognition

- Current clinically-significant systemic illness that is likely to result in
deterioration of the patient's condition or affect the patient's safety during the
study.

- History of clinically-evident stroke

- Clinically-significant infection within the last 30 days

- Myocardial infarction or symptoms of active coronary artery disease (e.g., angina) in
the last two years.

- Uncontrolled hypertension within the last 6 months.

- History of cancer within the last 5 years (except non-metastatic basal or squamous
cell carcinoma)

- History of drug or alcohol abuse as defined by DSM-IV criteria within the last 2
years

- Insulin dependent diabetes mellitus

- Significant pain or musculoskeletal disorder that would prohibit participation in
metabolic testing